Erivedge® Pregnancy Prevention Programme
Erivedge® Pregnancy Prevention Programme
The Pregnancy Prevention Programme (PPP) provides education to both Healthcare Providers (HCPs) and patients on the risk of teratogenicity and mandates contraceptive measures to prevent fetal exposure.
The objectives of the PPP are:
- To inform patients and HCPs of the teratogenic risks to the fetus that are associated with vismodegib use
- To prevent Erivedge exposure in pregnant women, by mandating pregnancy testing and contraception requirements
- To provide guidelines for the prescription of Erivedge in women of child bearing potential (WCBP) and male partners of WCBP
*These materials are approved by the European Medicines Agency (EMA). Different versions in local languages can be found under “Erivedge in your country”
**Currently approved by the European Medicines Agency (EMA), including approved EU translations in local languages